Biotechnology California, USA-based biotech Nymox Pharmaceutical saw its shares plunge as much as 64% yesterday, after it said it has received a Refusal to File (RTF) letter from the Food and Drug Administration on regarding the company's New Drug Application (NDA) for fexapotide triflutate, its candidate for the treatment of benign hyperplasia (BPH). 25 May 2022